Contribution of Selected Gene Mutations to Resistance in Clinical Isolates of Vancomycin-Intermediate Staphylococcus aureus
暂无分享,去创建一个
F. Lowy | Ying Lin | J. Kornblum | A. Uhlemann | C. Hafer
[1] Boris M. Hartmann,et al. Genetic Pathway in Acquisition and Loss of Vancomycin Resistance in a Methicillin Resistant Staphylococcus aureus (MRSA) Strain of Clonal Type USA300 , 2012, PLoS pathogens.
[2] Torsten Seemann,et al. Evolution of Multidrug Resistance during Staphylococcus aureus Infection Involves Mutation of the Essential Two Component Regulator WalKR , 2011, PLoS pathogens.
[3] F. Lowy,et al. The Environment as an Unrecognized Reservoir for Community-Associated Methicillin Resistant Staphylococcus aureus USA300: A Case-Control Study , 2011, PloS one.
[4] L. Cui,et al. Mutation of RNA Polymerase β Subunit (rpoB) Promotes hVISA-to-VISA Phenotypic Conversion of Strain Mu3 , 2011, Antimicrobial Agents and Chemotherapy.
[5] L. Cui,et al. walK and clpP Mutations Confer Reduced Vancomycin Susceptibility in Staphylococcus aureus , 2011, Antimicrobial Agents and Chemotherapy.
[6] L. Cui,et al. Impact of rpoB Mutations on Reduced Vancomycin Susceptibility in Staphylococcus aureus , 2011, Journal of Clinical Microbiology.
[7] A. Gikas,et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. , 2010, American journal of infection control.
[8] Paul D. R. Johnson,et al. Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications , 2010, Clinical Microbiology Reviews.
[9] M. Rybak,et al. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. , 2009, The Journal of antimicrobial chemotherapy.
[10] L. Cui,et al. Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.
[11] D. Allen,et al. Genomic Analysis Reveals a Point Mutation in the Two-Component Sensor Gene graS That Leads to Intermediate Vancomycin Resistance in Clinical Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.
[12] M. Wootton,et al. Evaluation of a New Etest Vancomycin-Teicoplanin Strip for Detection of Glycopeptide-Intermediate Staphylococcus aureus (GISA), in Particular, Heterogeneous GISA , 2008, Journal of Clinical Microbiology.
[13] A. Mellmann,et al. Characterization of Clonal Relatedness among the Natural Population of Staphylococcus aureus Strains by Using spa Sequence Typing and the BURP (Based upon Repeat Patterns) Algorithm , 2008, Journal of Clinical Microbiology.
[14] J. Stoye,et al. Based Upon Repeat Pattern (BURP): an algorithm to characterize the long-term evolution of Staphylococcus aureus populations based on spa polymorphisms , 2007, BMC Microbiology.
[15] H. Yuzawa,et al. Mutated Response Regulator graR Is Responsible for Phenotypic Conversion of Staphylococcus aureus from Heterogeneous Vancomycin-Intermediate Resistance to Vancomycin-Intermediate Resistance , 2007, Antimicrobial Agents and Chemotherapy.
[16] H. de Lencastre,et al. Multiplex PCR strategy for subtyping the staphylococcal cassette chromosome mec type IV in methicillin-resistant Staphylococcus aureus: 'SCCmec IV multiplex'. , 2007, The Journal of antimicrobial chemotherapy.
[17] H. de Lencastre,et al. Update to the Multiplex PCR Strategy for Assignment of mec Element Types in Staphylococcus aureus , 2007, Antimicrobial Agents and Chemotherapy.
[18] Alexander Tomasz,et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing , 2007, Proceedings of the National Academy of Sciences.
[19] F. Tenover,et al. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] S. Yin,et al. The VraS/VraR two-component regulatory system required for oxacillin resistance in community-acquired methicillin-resistant Staphylococcus aureus. , 2006, FEMS microbiology letters.
[21] James G. Johnson,et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] P. Ward,et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] A. Tomasz,et al. High Level Oxacillin and Vancomycin Resistance and Altered Cell Wall Composition in Staphylococcus aureus Carrying the Staphylococcal mecA and the Enterococcal vanA Gene Complex* , 2004, Journal of Biological Chemistry.
[24] J. Rothgänger,et al. Typing of Methicillin-Resistant Staphylococcus aureus in a University Hospital Setting by Using Novel Software for spa Repeat Determination and Database Management , 2003, Journal of Clinical Microbiology.
[25] A. Tomasz,et al. Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus under the Impact of Antibiotics Administered for Chemotherapy , 2003, Journal of Clinical Microbiology.
[26] G. Eliopoulos,et al. Accessory Gene Regulator (agr) Locus in Geographically Diverse Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin , 2002, Antimicrobial Agents and Chemotherapy.
[27] A. MacGowan,et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. , 2001, The Journal of antimicrobial chemotherapy.
[28] C. Martín,et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital , 1998, The Lancet.
[29] Y. Fukuchi,et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.
[30] Takahisa Suzuki,et al. Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. , 2010, The Journal of antimicrobial chemotherapy.
[31] G. Eliopoulos,et al. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[33] B. Spratt,et al. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. , 2000, Journal of clinical microbiology.
[34] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .